JPWO2021148411A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021148411A5 JPWO2021148411A5 JP2022544144A JP2022544144A JPWO2021148411A5 JP WO2021148411 A5 JPWO2021148411 A5 JP WO2021148411A5 JP 2022544144 A JP2022544144 A JP 2022544144A JP 2022544144 A JP2022544144 A JP 2022544144A JP WO2021148411 A5 JPWO2021148411 A5 JP WO2021148411A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- mydgf
- heart failure
- nucleic acid
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100031789 Myeloid-derived growth factor Human genes 0.000 claims description 42
- 101710164766 Myeloid-derived growth factor Proteins 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 230000002265 prevention Effects 0.000 claims description 20
- 230000008827 biological function Effects 0.000 claims description 18
- 206010016654 Fibrosis Diseases 0.000 claims description 17
- 206010019280 Heart failures Diseases 0.000 claims description 17
- 206010020880 Hypertrophy Diseases 0.000 claims description 17
- 230000004761 fibrosis Effects 0.000 claims description 17
- 230000001747 exhibiting effect Effects 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims description 9
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 7
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 10
- 239000003937 drug carrier Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20153008.6 | 2020-01-21 | ||
| EP20153008 | 2020-01-21 | ||
| PCT/EP2021/051079 WO2021148411A1 (fr) | 2020-01-21 | 2021-01-19 | Facteur de croissance dérivé de la protéine myéloïde destiné à être utilisé dans le traitement ou la prévention de la fibrose, de l'hypertrophie ou de l'insuffisance cardiaque |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511358A JP2023511358A (ja) | 2023-03-17 |
| JPWO2021148411A5 true JPWO2021148411A5 (fr) | 2024-01-26 |
Family
ID=69187588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544144A Pending JP2023511358A (ja) | 2020-01-21 | 2021-01-19 | 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230059560A1 (fr) |
| EP (1) | EP4093750A1 (fr) |
| JP (1) | JP2023511358A (fr) |
| KR (1) | KR20220131262A (fr) |
| CN (1) | CN115698048A (fr) |
| AU (1) | AU2021211874A1 (fr) |
| BR (1) | BR112022014272A2 (fr) |
| CA (2) | CA3164500A1 (fr) |
| MX (1) | MX2022008727A (fr) |
| TW (1) | TW202142254A (fr) |
| WO (1) | WO2021148411A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11980654B2 (en) | 2020-09-22 | 2024-05-14 | Wisconsin Alumni Research Foundation | Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor |
| CA3202675A1 (fr) | 2020-12-23 | 2022-06-30 | Thorsten Lamla | Proteines de capside virale ayant une specificite pour des cellules de tissu cardiaque |
| WO2023233034A1 (fr) | 2022-06-03 | 2023-12-07 | Boehringer Ingelheim International Gmbh | Expression recombinante du facteur de croissance dérivé de myéloïde |
| WO2024052563A1 (fr) | 2022-09-08 | 2024-03-14 | Boehringer Ingelheim International Gmbh | Facteur de croissance dérivé de myéloïde destiné à être utilisé dans le traitement d'un choc cardiogénique |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (fr) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Composés recombinants d'ADN et l'expression de polypeptides comme le tPA |
| JP2002500502A (ja) | 1996-06-11 | 2002-01-08 | メルク エンド カンパニー インコーポレーテッド | 合成ｃ型肝炎遺伝子 |
| WO1998011217A2 (fr) * | 1996-09-13 | 1998-03-19 | Sagami Chemical Research Center | Proteines humaines comportant des sequences de signaux secretoires et adn codant ces proteines |
| WO2004069173A2 (fr) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Procedes pour moduler une reaction inflammatoire |
| US20080004232A1 (en) | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP2130547A1 (fr) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 pour le traitement des maladies inflammatoires |
| CN110922468A (zh) | 2013-01-17 | 2020-03-27 | 汉诺威医学院 | 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂 |
| EP3790572A4 (fr) * | 2018-05-09 | 2022-03-16 | Keros Therapeutics, Inc. | Variants du récepteur de l'activine de type iia et leurs procédés d'utilisation |
-
2021
- 2021-01-19 EP EP21701283.0A patent/EP4093750A1/fr active Pending
- 2021-01-19 US US17/759,056 patent/US20230059560A1/en active Pending
- 2021-01-19 MX MX2022008727A patent/MX2022008727A/es unknown
- 2021-01-19 KR KR1020227027546A patent/KR20220131262A/ko active Search and Examination
- 2021-01-19 JP JP2022544144A patent/JP2023511358A/ja active Pending
- 2021-01-19 CA CA3164500A patent/CA3164500A1/fr active Pending
- 2021-01-19 CN CN202180022864.1A patent/CN115698048A/zh active Pending
- 2021-01-19 BR BR112022014272A patent/BR112022014272A2/pt unknown
- 2021-01-19 AU AU2021211874A patent/AU2021211874A1/en active Pending
- 2021-01-19 CA CA3223879A patent/CA3223879A1/fr active Pending
- 2021-01-19 TW TW110102010A patent/TW202142254A/zh unknown
- 2021-01-19 WO PCT/EP2021/051079 patent/WO2021148411A1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3566283B2 (ja) | 心臓疾患の予防又は治療用の医薬組成物 | |
| US5798102A (en) | Treatment of cardiomyopathy | |
| CN1993137B (zh) | 用于治疗心血管疾病的组合物和方法 | |
| US11298403B2 (en) | Therapeutic agent for inflammatory bowel disease | |
| JP2010512393A5 (fr) | ||
| US11414474B2 (en) | Long-acting adrenomedullin derivatives | |
| JP2013155193A (ja) | Ｆｇｆの脈管形成的に有効な単位用量および投与方法 | |
| US11993638B2 (en) | GM-CSF mimetics and methods of making and using same | |
| JP2008540457A (ja) | 心臓血管疾患の治療 | |
| TW201832776A (zh) | 心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物 | |
| Bourdillon et al. | Salbutamol in treatment of heart failure. | |
| US8404653B2 (en) | Membrane bound stem cell factor therapy for ischemic heart | |
| US9060977B2 (en) | Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation | |
| JPWO2021148411A5 (fr) | ||
| JPWO2020055812A5 (fr) | ||
| US20150231205A1 (en) | Compositions and methods for the treatment of myocardial ischemia/reperfusion injury with annexin a1 short peptide | |
| JP7411154B2 (ja) | コドン最適化ＴＩＦ１γポリヌクレオチドを含む組換えベクターおよびその用途 | |
| WO1999027951A1 (fr) | Preparation pour l'admission intraveineuse continue | |
| WO2006125200A2 (fr) | Procede pour reduire un choc septique ou cardiogene associe a une lesion du myocarde | |
| JP4831551B2 (ja) | 非虚血性心筋障害に対する医薬 | |
| JPWO2019183333A5 (fr) | ||
| CN114369598A (zh) | 一种靶向型针对LRRK2的siRNA表达质粒及其在帕金森氏症方面的应用 | |
| CN118252920A (zh) | 携带白介素10的溶瘤病毒在结直肠癌肝转移领域中的应用 | |
| KR20070032005A (ko) | 심혈관 질환의 치료를 위한 조성물 및 방법 | |
| JPWO2020026167A5 (fr) |